Available in 10 markets
State Street® SPDR® S&P® Pharmaceuticals ETF
State Street® SPDR® S&P® Pharmaceuticals ETF is an exchange-traded fund (ETF) from SPDR, traded under the ticker XPH (ISIN US78464A7220). One trade buys a whole basket of holdings, so your money is spread out instead of riding on a single company. At its core it is a focused, thematic fund: it concentrates on the health care part of the market,…
Opens the screener with this filter applied.
About this fund
What you own
The S&P Pharmaceuticals Select Industry Index index is the benchmark this fund aims to copy. By holding it, this fund gives you a stake in around 67 companies across Other in a single purchase.
How it works
The fund actually buys every share in the index it tracks (full replication).
Read more
Owning every holding keeps things transparent — what is in the index is what the fund actually owns. It can be a touch costlier to run for indexes with thousands of tiny positions, since the fund has to buy and maintain them all. There is no swap bank involved, so there is no extra “what if the partner fails” question to weigh.
Cost
The yearly running cost of the fund, shown as a % of your money. Lower is cheaper.
Read more
For example, a 0.20% fee works out at €0.20 a year for every €100 invested — that’s a generic illustration of the mechanic, not this fund’s own fee. It is skimmed quietly from inside the fund a little each day, so you never get a bill — but it drags on your return every year you hold. On a broad index ETF it is usually a small fraction of a percent; the gap between a cheap and a pricey fund looks tiny on day one but compounds over decades, which is why it is worth a glance.
Fund facts
Performance
Growth of $100 invested — the line starts at $100.
End-of-day prices, rebased to a common start so the shapes are comparable. Past performance does not predict future results.
Return, year by year
How bumpy has it been?
The bigger picture
What's inside
By sector ?
The 10 biggest holdings make up 27.0% of the fund — the rest is spread across roughly 57 more companies.
Top 10 holdings
| # | Company | Weight |
|---|---|---|
| 1 | AMYLYX PHARMACEUTICALS INC | 4.0% |
| 2 | CRINETICS PHARMACEUTICALS IN | 3.4% |
| 3 | MBX BIOSCIENCES INC | 3.1% |
| 4 | DEFINIUM THERAPEUTICS INC | 2.7% |
| 5 | ATAIBECKLEY INC | 2.7% |
| 6 | OMEROS CORP | 2.5% |
| 7 | ENLIVEN THERAPEUTICS INC | 2.2% |
| 8 | NUVATION BIO INC | 2.2% |
| 9 | CORCEPT THERAPEUTICS INC | 2.1% |
| 10 | ETON PHARMACEUTICALS INC | 2.0% |
Where to buy this fund
Set from your language & location — change it if it's wrong.
Where it trades
| Exchange | Ticker | Currency | |
|---|---|---|---|
| NYSE | XPH | USD | ★ Primary |
| EUR listings | |||
| Frankfurt | SSGE | EUR | |
| USD listings | |||
| B2 | XPHUSD | USD | |
| B4 | XPHUSD | USD | |
| E1 | XPHGBP | USD | |
| E1 | XPHRUB | USD | |
| E1 | XPHUSD | USD | |
| EO | XPHRUB | USD | |
| EU | XPH1 | USD | |
| EU | XPHGBP | USD | |
| EU | XPHRUB | USD | |
| EU | XPHUSD | USD | |
| GH | SSGE | USD | |
| GI | SSGE | USD | |
| MF | XPH* | USD | |
| MM | XPH* | USD | |
| MU | XPH* | USD | |
| NYSE Arca | XPH | USD | |
| OC | XPH | USD | |
| TH | SSGE | USD | |
| UA | XPH | USD | |
| UB | XPH | USD | |
| UC | XPH | USD | |
| UD | XPH | USD | |
| UF | XPH | USD | |
| UM | XPH | USD | |
| US | XPH | USD | |
| UT | XPH | USD | |
| UX | XPH | USD | |
| VF | XPH | USD | |
| VG | XPH | USD | |
| VJ | XPH | USD | |
| VK | XPH | USD | |
| VP | XPH | USD | |
| VY | XPH | USD | |
| X2 | XPHUSD | USD | |
| XA | XPHGBP | USD | |
| XA | XPHRUB | USD | |
| XA | XPHUSD | USD | |
| XB | XPHUSD | USD | |
| XE | XPHUSD | USD | |
| XE | XPHRUB | USD | |
| XE | XPHGBP | USD | |
| XF | XPHGBP | USD | |
| XF | XPHRUB | USD | |
| XF | XPHUSD | USD | |
| XG | XPHUSD | USD | |
| XG | XPHRUB | USD | |
| XG | XPHGBP | USD | |
| XH | XPHGBP | USD | |
| XH | XPHRUB | USD | |
| XH | XPHUSD | USD | |
| XJ | XPHUSD | USD | |
| XJ | XPHRUB | USD | |
| XJ | XPHGBP | USD | |
| XL | XPHGBP | USD | |
| XL | XPHRUB | USD | |
| XL | XPHUSD | USD | |
| XO | XPHGBP | USD | |
| XO | XPHRUB | USD | |
| XO | XPHUSD | USD | |
| XQ | XPHUSD | USD | |
| XQ | XPHRUB | USD | |
| XQ | XPHGBP | USD | |
| XS | XPHGBP | USD | |
| XS | XPHUSD | USD | |
| XT | XPHRUB | USD | |
| XU | XPHGBP | USD | |
| XU | XPHRUB | USD | |
| XU | XPHUSD | USD | |
| XV | XPHUSD | USD | |
| XV | XPHRUB | USD | |
| XV | XPHGBP | USD | |
| XW | XPHGBP | USD | |
| XW | XPHRUB | USD | |
| XW | XPHUSD | USD | |
| XX | XPHUSD | USD | |
| XX | XPHRUB | USD | |
| XX | XPHGBP | USD | |
| XZ | XPHGBP | USD | |
| XZ | XPHRUB | USD | |
| XZ | XPHUSD | USD | |
For serious comparison — full data holdings, percentiles, advanced risk, tilt, flows
Full holdings
As of 2026-09-10 · the fund's own published holdings.
| # | Company | Weight |
|---|---|---|
| 1 | AMYLYX PHARMACEUTICALS INC | 4.0% |
| 2 | CRINETICS PHARMACEUTICALS IN | 3.4% |
| 3 | MBX BIOSCIENCES INC | 3.1% |
| 4 | DEFINIUM THERAPEUTICS INC | 2.7% |
| 5 | ATAIBECKLEY INC | 2.7% |
| 6 | OMEROS CORP | 2.5% |
| 7 | ENLIVEN THERAPEUTICS INC | 2.2% |
| 8 | NUVATION BIO INC | 2.2% |
| 9 | CORCEPT THERAPEUTICS INC | 2.1% |
| 10 | ETON PHARMACEUTICALS INC | 2.0% |
| 11 | EDGEWISE THERAPEUTICS INC | 2.0% |
| 12 | TREVI THERAPEUTICS INC | 2.0% |
| 13 | OCULAR THERAPEUTIX INC | 1.9% |
| 14 | NEKTAR THERAPEUTICS | 1.9% |
| 15 | MERCK + CO. INC. | 1.8% |
| 16 | PERRIGO CO PLC | 1.7% |
| 17 | BRISTOL MYERS SQUIBB CO | 1.7% |
| 18 | MAZE THERAPEUTICS INC | 1.7% |
| 19 | TARSUS PHARMACEUTICALS INC | 1.7% |
| 20 | VERADERMICS INC | 1.7% |
| 21 | ALUMIS INC | 1.7% |
| 22 | AMNEAL PHARMACEUTICALS INC | 1.6% |
| 23 | LIGAND PHARMACEUTICALS | 1.6% |
| 24 | HARROW INC | 1.6% |
| 25 | LIQUIDIA CORP | 1.6% |
| 26 | JOHNSON + JOHNSON | 1.6% |
| 27 | ROYALTY PHARMA PLC CL A | 1.6% |
| 28 | ELI LILLY + CO | 1.6% |
| 29 | HARMONY BIOSCIENCES HOLDINGS | 1.6% |
| 30 | RAPPORT THERAPEUTICS INC | 1.5% |
| 31 | PFIZER INC | 1.5% |
| 32 | JAZZ PHARMACEUTICALS PLC | 1.5% |
| 33 | SUPERNUS PHARMACEUTICALS INC | 1.5% |
| 34 | ELANCO ANIMAL HEALTH INC | 1.5% |
| 35 | PRESTIGE CONSUMER HEALTHCARE | 1.5% |
| 36 | PACIRA BIOSCIENCES INC | 1.4% |
| 37 | VIATRIS INC | 1.4% |
| 38 | ORGANON + CO | 1.4% |
| 39 | INDIVIOR PHARMACEUTICALS INC | 1.4% |
| 40 | ALTO NEUROSCIENCE INC | 1.4% |
| 41 | XERIS BIOPHARMA HOLDINGS INC | 1.4% |
| 42 | WAVE LIFE SCIENCES INC | 1.3% |
| 43 | ANI PHARMACEUTICALS INC | 1.3% |
| 44 | ARVINAS INC | 1.3% |
| 45 | PHIBRO ANIMAL HEALTH CORP A | 1.3% |
| 46 | ZOETIS INC | 1.3% |
| 47 | INNOVIVA INC | 1.3% |
| 48 | AXSOME THERAPEUTICS INC | 1.2% |
| 49 | AMPHASTAR PHARMACEUTICALS IN | 1.2% |
| 50 | SEPTERNA INC | 1.2% |
| 51 | COLLEGIUM PHARMACEUTICAL INC | 1.1% |
| 52 | LB PHARMACEUTICALS INC | 1.1% |
| 53 | CORMEDIX INC | 1.0% |
| 54 | ACLARIS THERAPEUTICS INC | 1.0% |
| 55 | ZEVRA THERAPEUTICS INC | 1.0% |
| 56 | THERAVANCE BIOPHARMA INC | 0.9% |
| 57 | PHATHOM PHARMACEUTICALS INC | 0.8% |
| 58 | AQUESTIVE THERAPEUTICS INC | 0.8% |
| 59 | EYEPOINT INC | 0.7% |
| 60 | RELMADA THERAPEUTICS INC | 0.7% |
| 61 | FULCRUM THERAPEUTICS INC | 0.7% |
| 62 | BIOAGE LABS INC | 0.6% |
| 63 | EVOLUS INC | 0.6% |
| 64 | LEXICON PHARMACEUTICALS INC | 0.6% |
| 65 | SSI US GOV MONEY MARKET CLASS | 0.1% |
| 66 | CONTRA ESPERION THERAP | 0.0% |
| 67 | US DOLLAR | 0.0% |
How it ranks vs peers
Versus the Equity (stocks) · Other · USD ETFs we track.
Advanced risk
Concentration depth
Roughly 67 companies are held, but the largest names carry most of the weight — so it behaves like ~55 equal-sized positions.
Tilt vs a world tracker
Percentage points over / under a broad world-equity tracker (not a licensed benchmark).
Similar funds
We found 6 funds that do much the same job as this one. To pick them we matched this fund's asset class and region, then show how close each match is below.
| State Street® SPDR® S&P® Pharmaceuticals ETFSPDRYou're viewing | State Street® Technology Select Sector SPDR® ETFSPDRBroader match | Schwab International Equity ETFSchwabBroader match | State Street® Financial Select Sector SPDR® ETFSPDRBroader match | State Street® Health Care Select Sector SPDR® ETFSPDRBroader match | State Street® Energy Select Sector SPDR® ETFSPDRBroader match | State Street® Industrial Select Sector SPDR® ETFSPDRBroader match | |
|---|---|---|---|---|---|---|---|
| Why it's similar | This is the fund on this page. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. | StocksUnknownPhysicalCheaper fee Tracks a different index in the same category. |
| Index tracked | S&P Pharmaceuticals Select Industry Index | Technology Select Sector Index | FTSE Developed ex US Index | Financial Select Sector Index | Health Care Select Sector Index | Energy Select Sector Index | Industrial Select Sector Index |
| Yearly fee (TER) | 0.35% | 0.08% | 0.03% | 0.08% | 0.08% | 0.08% | 0.08% |
| All-in cost | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Fund size | €520.4M | €104.5B | €56.6B | €47.7B | €38.4B | €36.7B | €27.4B |
| Domicile | United States | United States | United States | United States | United States | United States | United States |
| Replication | Physical (full) | Physical (full) | Physical (full) | Physical (full) | Physical (full) | Physical (full) | Physical (full) |
| 3-yr return p.a. | +16.3% | +28.4% | +13.9% | +18.7% | +8.2% | +12.1% | +18.2% |
| 5-yr return p.a. | +7.2% | +18.6% | +6.7% | +8.6% | +4.5% | +22.1% | +11.2% |
| # holdings | 67 | 76 | 1,494 | 80 | 63 | 24 | 86 |
The fund on this page stays pinned on the left — scroll or use ‹ › to compare it against each one.
Open the full comparison tool →New to ETFs? Start with the basics →
Finance Hamster provides educational information about ETFs and investing. It is not investment, tax, or legal advice, and not a recommendation to buy or sell any security. Markets carry risk; do your own research or consult a licensed adviser.